medwireNews

The multikinase inhibitor anlotinib is effective and well tolerated in advanced non-small-cell lung cancer patients who have used at least two prior lines of systemic therapy, phase III trial results suggest.

Short-term induction therapy with a tumor necrosis factor inhibitor plus methotrexate could alter disease development in some patients with early rheumatoid arthritis, providing long-term benefit, results of the DINORA trial suggest.

The Addressing Behavior Change intervention, which can be delivered by dermatologists in less than 3 minutes, is associated with improvements in people’s sun protection behavior that last several months, findings indicate.

Findings from a large registry-based study support an increased risk of suicide following traumatic brain injury.

Two studies have described factors associated with the achievement of sustained remission among patients with rheumatoid arthritis.

Oral etoposide plus apatinib is associated with a good objective response rate and manageable toxicity in heavily pretreated Chinese women with platinum-resistant or refractory ovarian cancer, according to results of the phase II AEROC study.